7/27/2019 sindrome nefritik
1/5
| 1IJzer en nierschade
Tabel 1.Overzicht rol van ijzer bij nierschade in dierexperimentele studies
Mechanisme Diermodel Onderzoeksresultaten Ref
Heem-genduceerdenierschade
HA IJzer in cortex33 33HIV-HUS model IJzer in PT
IJzer in urine39
Rhabdomyolyse IJzer in cortex, i jzer in PT, BDI in de nier DFO therapie GFR
22,23,32,34
Hemoglobine IJzer in distale nephron (ook PT )DFO inuline klaring
24,32
Systemischeijzerstapeling
HH (Hepc-/-, HJV-/-) IJzer in medulla en enkele cortex tubuliIJzer in urine
25
HH (HFE-/-) NHI, totaal ijzer niet signi cant hoger 35Nierschade bijhematurie enprotenurie
Spontane GS enprotenurie
IJzerde cint dieet protenurie , glomerulosclerose ,hypertensie (p
7/27/2019 sindrome nefritik
2/5
2 | Capita Selecta Nefrologie | nummer 2, 2012
Tabel 2.Overzicht rol van ijzer bij nierschade in humane studies
Mechanisme Ziektebeeld Onderzoeksresultaten Ref Heem-genduceerdenierschade
Intravasculairehemolyse
IJzer in tubuli, PT en LoH, Hbur , HSur . Protenurie, hematurie, ATN 17,55,56,61,69
PNH IJzer in nier, cortex, tubuli, PT en urineTI schade, protenurie, interstitile brose
17,58-60,89
HIV-HUS IJzer in PT en urine 39
Systemischeijzerstapeling SCA IJzer in cortex, tubuli, glomeruli en urine 17,57,62Thalassemie IJzer in nier, glomeruli , tubuli (DT>PT) en inters tit iumDes errioxamine-B therapie tolerantie NAGur
17,54,64,71
Trans usionele ijzer-stapeling
Toename ijzer in corticomedullair grensgebied 63
HH IJzer in DT, LoH en glomeruli, hemosiderinurie 65Nierschade bijhematurie enprotenurie
GN IJzer in urineDe eriprone therapie protenurie
3,76
Diabetes, DN IJzer in urine. UIE bij diabetespatinten is verhoogd vr het ontstaan vanprotenurieDe eriprone therapie Alb/Createn stabilisatie nier unctie (in DN)
3,74,76
IMPG IJzer in urineProtenurie
108
IgA-ne ropathie Macroscopische hematur ieATN in tubuli verstopt met RBC restenDuur van hematurie corr. met naal Scr IJzerdepositie in nier corr. met NAGur
67,68
CKD IJzer in PTLysosomale ijzer in PT corr. met protenurieTubulaire schade corr. met lysosomale ijzer. IJzerdepositie in nier corr. met NAGur EDTA therapie vertraging progressie nierziekte
66,67,75
Ne rotisch syndroom(MG en FG, MCGN)
IJzer in urine, protenurieUIE corr. met T ur T ur corr. met protenurie
16,73
Alb: Albumine; ATN: Acute tubulaire necrose; corr: correleert; DN: Diabetische ne ropathie; FG: ocale glomerulone ritis; Hbur :Hemoglobinurie; HH: Hereditaire hemochromatose; HIV-HUS: HIV-geassocieerde hemolytisch uremisch syndroom; HSur : Hemosiderinurie;IMPG: Idiopatische membranoproli eratieve glomerulone ritis; MCGN: Minimal change glomerulone ritis; MG: Membraneus glomerulone ritisLoH: Loop o Henle; MH: Mechanische hemolyse; NAGur : N-acetyl-b-D-glucosaminidase in urine; PNH: Paroxysmal nachtelijke hemoglubinurie;RBC: rode bloedcel; Re : Re erenties; SCA: Sickle cell anemie; Scr: Serum creatinine; T ur : Trans errine in urine; TM: Thalassemia major
7/27/2019 sindrome nefritik
3/5
7/27/2019 sindrome nefritik
4/5
4 | Capita Selecta Nefrologie | nummer 2, 2012
46. Walker P.D., Shah S.V. Evidence suggesting a role or hydroxyl radical in gen-tamicin-induced acute renal ailure in rats. Journal of Cl inical Investigation 1988,81, 334-41.
47. Zager R.A., Burkhart K. Myoglobin toxicity in proximal human kidney cells:Roles o Fe, Ca2+, H2O2, and terminal mitochondrial electron transport.Kidney International 1997,51, 728-38.
48. Sheerin N.S., Sacks S.H., Fogazzi G.B. In vitro erythrophagocy tosis by renaltubular cells and tubular toxicity by haemoglobin and iron.Nephrology Dialysis Transplantation 1999,14 , 1391-7.
49. Zager R.A. Combined mannitol and de eroxamine therapy or myohemoglo-binuric renal injury and oxidant tubular stress. Mechanistic and therapeuticimplications. Journal of Cl inical Investigation 1992,90 , 711-9.
50. Sponsel H.T., Al rey A.C., Hammond W.S., Durr J.A. , Ray C., Anderson R.J.E ect o iron on renal tubular epithelial cells.Kidney International 1996,50 ,436-44.
51. Chen L., Boadle R.A., Harris D.C.H. Toxicity o holotrans errin but not albu-min in proximal tubule cells in primary culture. Jour nal of the Ameri can Society of Nephrology 1998,9 , 77-84.
52. Paller M.S., Hedlund B.E. Extracellul ar iron chelators protect kidney cellsrom hypoxia/reoxygenation.Free Radical Biology and Medicine 1994,17 ,
597-603.53. De Vries B., Walter S.J., Von Bonsdor L., Wol s T.G.A.M., Van Heurn L.W.E.,
Parkkinen J., et al. Reduction o circulating redox-active iron by apotrans err inprotects against renal ischemia-reper usion injury.Transplantation 2004,77 ,669-75.
54. Hashemieh M., Azarkeivan A., Akhlaghpoor S., Shirkavand A., Sheibani K.T2-star (T2*) magnetic resonance imaging or assessment o kidney ironoverload in thalassemic patients. Archives of Iranian Medicine 2012,15 , 91-4.
55. LEONARDI P., RUOL A. Renal hemosiderosis in the hemolytic anemias:diagnosis by means o needle biopsy.Blood 1960,16 , 1029-38.
56. Qian Q., Nath K.A ., Wu Y., Daoud T.M., Sethi S. Hemolysis and acute kidneyailure. American Jou rnal of K idney D iseases 2010,56 , 780-4.
57. Schein A., Enriquez C., Coates T.D., Wood J.C. Magnetic resonance detection o kidney iron deposition in sickle cell disease: A marker o chronic hemolysis.
Journal of Magnetic Re sonance Imag ing 2008,28 , 698-704.
58. Suzukawa K., Ninomiya H., Mitsuhashi S., Anno I., Nagasawa T., Abe T.Demonstration o the deposition o hemosiderin in the kidneys o patientswith paroxysmal nocturnal hemoglobinuria by magnetic resonance imaging.Internal medicine (Tokyo, Japan) 1993,32 , 686-90.
59. Hsiao P.J., Wang S.C., Wen M.C., Diang L.K., Lin S.H. Fanconi Syndromeand CKD in a Patient With Paroxysmal Nocturnal Hemoglobinuria andHemosiderosis. Americ an Journal of K idney Diseases 2010,55 , e1-e5.
60. Ballarn J., Arce Y., Torra Balcells R., az Encarnacin M., Manzarbeitia F.,Ortiz A., et al. Acute renal ailure associated to paroxysmal nocturnalhaemoglobinuria leads to intratubular haemosiderin accumulation andCD163 expression.Nephrology Dialysis Transplantation 2011,26 , 3408-11.
61. Fervenza F.C., Croatt A.J. , Bittar C.M., Rosenthal D.W., Lager D.J., Leung N.,et al. Induction o Heme Oxygenase-1 and Ferritin in the Kidney in Warm
Antibody Hemolytic Anemia. American Journa l of Kidney Diseases 2008,52 ,972-7.
62. Buckalew Jr V.M., Someren A. Renal mani estations o sickle cell disease. Archives of Interna l Medicine 133 , 660-669. 1974. Re Type: Abstract
63. Rakow-Penner R., Glader B., Yu H., Vasanawala S. Adrenal and renal cortico-medullary junction iron deposition in red cell aplasia.Pediatric Radiology 2010,40 , 1955-7.
64. Buhl L., Muirhead D.E., Prentis P.F. Renal hemosiderosis due to thalassemia: Alight and electron microscopy study with electron probe X-ray microanalysis.Ultrastructural Pathology 1993,17 , 169-83.
65. Rous P. URINARY SIDEROSIS : HEMOSIDERIN GRANULES IN THEURINE AS AN AID IN THE DIAGNOSIS OF PERNICIOUS ANEMIA,HEMOCHROMATOSIS, AND OTHER DISEASES CAUSING SIDEROSIS OF
THE KIDNEY. J Exp Med 1918,28 , 645-58.66. Nankivell B.J., Boadle R.A., Harris D.C.H. Iron accumulation in human
chronic renal disease. American Journal of Kidney Diseases 1992,20 , 580-4.
67. Wang H., Nishiya K., Ito H., Hosokawa T., Hashimoto K., Moriki T. Iron depositionin renal biopsy specimens rom patients with kidney diseases. American
Journal of Ki dney Di seases 2001,38 , 1038-44.68. Gutirrez E., Gonzlez E., Hernndez E., Morales E., Martnez M.A., Usera
G., et al. Factors that determine an incomplete recovery o renal unctionin macrohematuria-induced acute renal ailure o IgA nephropathy.Clinical
Journal of the American Soc iety of N ephro logy 2007,2 , 51-7.69. Yachie A., Niida Y., Wada T., Igarashi N., Kaneda H., Toma T., et al. Oxidative
stress causes enhanced endothelial cell injur y in human heme oxygenase-1de ciency. Journal of Cl inical Investigation 1999,103 , 129-35.
70. Aldudak B., Bayazit A.K., Noyan A., zel A., Anarat A., Sasmaz I., et al. Renalunction in pediatric patients withb -thalassemia major.Pediatric Nephrology
2000,15 , 109-12.71. Michelakakis H., Dimitriou E., Georgakis H., Karabatsos F., Fragodimitri C.,
Saraphidou J., et al. Iron overload and urinary lysosomal enzyme levels inb -thalassaemia major.European Journal of Pediatrics 1997,156 , 602-4.
72. Koliakos G., Papachristou F., Koussi A., Peri anis V., Tsatra I., Souliou E., etal. Urine biochemical markers o early renal dys unction are associated withiron overload inb -thalassaemia.Clinical and Laboratory Haematology 2003,25 , 105-9.
73. Prinsen B.H.C.M. , De Sain-van der Velden, Kaysen G.A. , Straver H.W.H.C.,Van Rijn H.J.M., Stellaard F., et al. Trans errin synthesis is increased innephrotic patients insu ciently to replace urinary losses. Journal of the
American Soc iety of N ephro logy 2001,12 , 1017-25.74. Howard R.L., Buddington B., Al rey A.C. Urinary albumin, trans errin and
iron excretion in diabetic patients.Kidney Int 1991,40 , 923-6.75. Lin J.L., Lin-Tan D.T., Hsu K.H., Yu C.C. Environmental lead exposure and
progression o chronic renal diseases in patients without diabetes.New England Journal of Medicine 2003,348 , 277-86.
76. Rajapurkar M.M., Hegde U., Bhattacharya A., Alam M.G., Shah S.V. E ect o De eriprone, an Oral Iron Chelator, in Diabetic and Non-diabetic Glomerular Disease. Toxicology Mechanisms and Methods 2012, 1-22.
77. Brittenham G.M. Iron-chelating therapy or trans usional iron overload.New England Journal of Medicine 2011,364 , 146-56.
78. Dubourg L, Laurain C, Ranchin B, Pondarr+ C, Hadj-A+ssa A, Sigaudo-
Roussel D, et al. De erasirox-induced renal impairment in children: anincreasing concern or pediatricians. Pediatric Nephrology. In press 2012.
79. Kontoghiorghes G.J. A record o 1320 suspect, de erasirox-related, patientdeaths reported in 2009: Insu cient toxicity testing, low e cacy and lack o transparency may endanger the lives o iron loaded patients.Hemoglobin 2011,35 , 301-11.
80. Huang X.P., Thiessen J.J., Spino M., Templeton D.M. Transport o ironchelators and chelates across MDCK cell monolayers: Implications or ironexcretion during chelation therapy.International Journal of Hematology 2010,91, 401-12.
81. Abbas M., Nawaz R., Shahid M., Nawaz M., Alim M., Asi M.R. Evaluationo urinary excretion and renal clearance o de eriprone, creatinine, ironand zinc in human. Asi an Journa l of Che mis try 21, 4583-4592. 2009.
Re Type: Abstract82. Rheault M.N., Bechtel H., Neglia J.P., Kashtan C.E. Reversible Fanconi syn-
drome in a pediatric patient on de erasirox.Pediatric Blood and Cancer 2011,56 , 674-6.
83. Baum M. Renal Fanconi syndrome secondary to de erasirox: Where thereis smoke there is re. Journal of Pediatric Hemato logy /Oncology 2010,32 ,525-6.
84. Boutaud O., Roberts II L.J. Mechanism-based therapeutic approaches torhabdomyolysis-induced renal ailure.Free Radical Biology and Medicine 2011,51, 1062-7.
85. Rachidi S., Musallam K.M., Taher A.T. A closer look at paroxysmal nocturnalhemoglobinuria.European Journal of Internal Medicine 2010,21, 260-7.
86. Tolosano E., Fagoonee S., Morello N., Vinchi F., Fiorito V. Heme scavenging
and the other acets o hemopexin. Antiox idant s and Redox Signaling 2010,12 , 305-20.
7/27/2019 sindrome nefritik
5/5
| 5IJzer en nierschade
87. Levy A.P., Asleh R., Blum S., Levy N.S., Miller-Lotan R., Kalet-Litman S., etal. Haptoglobin: Basic and clinical aspects. Antioxidants and Redox Signaling 2010,12 , 293-304.
88. Tracz M.J., Alam J., Nath K.A. Physiology and pathophysiology o heme:Implications or kidney disease. Jou rnal of the American Soc iet y of Nephrology 2007,18 , 414-20.
89. Nath K.A., Vercellotti G.M., Grande J.P., Miyoshi H., Paya C.V., Manivel J.C.,et al. Heme protein-induced chronic renal infammation: Suppressive e ecto induced heme ox ygenase-11.Kidney Int 2001,59 , 106-17.
90. Wei Q., Hill W.D., Su Y., Huang S., Dong Z. Heme oxygenase-1 inductioncontributes to renoprotection by G-CSF during rhabdomyolysis-associatedacute kidney injury. American Journal of Physi ology Renal Phys iology 2011,301 , F162-F170.
91. Van Gorp H., Delputte P.L., Nauwynck H.J . Scavenger receptor CD163, aJack-o -all-trades and potential target or cell-directed therapy.Molecular Immunology 2010,47 , 1650-60.
92. Swinkels D.W., Janssen M.C.H., Bergmans J., Marx J.J.M. Hereditary hemo-chromatosis: Genetic complexity and new diagnostic approaches.Clinical Chemistry 2006,52 , 950-68.
93. Brissot P., Ropert M., Le Lan C., Loral O. Non-trans errin bound iron:A key role in iron overload and iron toxicity.Biochimica et Biophysica
Acta General S ubjec ts 2012,1820 , 403-10.94. Shah S.V., Rajapurkar M.M. The role o labile iron in kidney disease and
treatment with chelation.Hemoglobin 2009,33 , 378-85.95. Pawar R.D., Pitashny M., Gindea S., Tieng A.T., Levine B., Goilav B., et al.
Neutrophil gelatinase-associated lipocalin is instrumental in the pathogenesiso antibody-mediated nephritis in mice. Arthr itis and Rheumat ism 2012,64 ,1620-31.
96. Lipton P. Ischemic cell death in brain neurons.Physiological Reviews 1999,79 , 1431-568.
97. Voogd A., Sluiter W., Van Eijk H.G., Koster J.F. Low molecular weight iron andthe oxygen paradox in isolated rat hearts. Journal of Clin ical Inves tigat ion 1992,90 , 2050-5.
98. Haase M., Bellomo R., Haase-Fielit z A. Novel Biomarkers, Oxidative Stress,and the Role o Labile Iron Toxicity in Cardiopulmonary Bypass-Associated
Acute Kidney Injury. Journal of the American Coll ege of Cardiology 2010,55 ,2024-33.
99. Mishra J., Qing M.A., Prada A., Mitsne es M., Zahedi K., Yang J., et al.Identi cation o neutrophil gelatinase-associated lipocalin as a novel earlyurinary biomarker or ischemic renal injury. Journal of the American Soc iety of Nephrology 2003,14 , 2534-43.
100. Ho J., Lucy M., K rokhin O., Hayglass K., Pascoe E., Darroch G., et al.Mass Spectrometry-Based Proteomic Analysis o Urine in Acute KidneyInjury Following Cardiopulmonary Bypass: A Nested Case-Control Study.
American Journal of K idney D iseases 2009,53 , 584-95.101. Ho J., Reslerova M., Gali B., Gao A., Bestland J., Rush D.N., et al. Urinary hep-
cidin-25 and risk o acute kidney injury ollowing cardiopulmonary bypass.Clinical Journal of the American Society of Nephrology 6 , 2340-2346. 2011.Re Type: Abstract
102. Haase-Fielitz A., Mertens P.R., Plab M., Kuppe H., Hetzer R., WestermanM., et al. Urine hepcidin has additive value in ruling out cardiopulmonarybypass-associated acute kidney injury: An observational cohort study.Critical Care 2011,15 .
103. Prowle J.R., Ostland V., Calzavacca P., Licari E., Ligabo E.V., EcheverriJ.E., et al. Greater increase in urinary hepcidin predicts protection romacute kidney injury a ter cardiopulmonary bypass.Nephrology Dialysis Transplantation 2011.
104. Prowle J.R., Westerman M., Bellomo R. Urinary hepcidin: An inverse bio-marker o acute kidney injury a ter cardiopulmonary bypass?Current Opinion in Critical Care 2010,16 , 540-4.
105. Kozyraki R., Fy e J., Verroust P.J., Jacobsen C., utry-Varsat A., Gburek J., etal. Megalin-dependent cubilin-mediated endocytosis is a major pathway
or the apical uptake o trans errin in polarized epithelia.Proceedings of the National Academy of Sciences of the United States of America 2001,98 ,12491-6.
106. Barasch J, Qiu A, inventors; Mutant NGAL proteins and uses thereo . NewYork/United S tates patent WO/2011/149962. 2011 Dec 1.
107. Shah S.V. Evidence suggesting a role or hydroxyl radical in passive Heymannnephritis in rats. Americ an Jo urnal of Physio logy Renal Physiology 1988,254 , F337-F344.
108. Ellis D. Anemia in the course o the nephrotic syndrome secondary to trans-errin depletion.The Journal of Pediatrics 1977,90 , 953-5.